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ORIGINAL RESEARCH

Nicotinamide Adenine Dinucleotide Phosphate Oxidase 2 Regulates
LPS-Induced Inﬂammation and Alveolar Remodeling in the
Developing Lung
Heather L. Menden, Sheng Xia, Sherry M. Mabry, Angels Navarro, Michael F. Nyp, and Venkatesh Sampath
Department of Pediatrics, Division of Neonatology, Children’s Mercy Hospital, Kansas City, Missouri

Abstract
In premature infants, sepsis is associated with alveolar
simpliﬁcation manifesting as bronchopulmonary dysplasia.
The redox-dependent mechanisms underlying sepsis-induced
inﬂammation and alveolar remodeling in the immature lung
remain unclear. We developed a neonatal mouse model of sepsisinduced lung injury to investigate whether nicotinamide adenine
dinucleotide phosphate oxidase 2 (NOX2) regulates Toll-like
receptor (TLR)–mediated inﬂammation and alveolar remodeling.
Six-day-old NOX21/1 and NOX22/2 mice were injected with
intraperitoneal LPS to induce sepsis. Lung inﬂammation and
canonical TLR signaling were assessed 24 hours after LPS.
Alveolar development was examined in 15-day-old mice after LPS
on Day 6. The in vivo efﬁcacy of a NOX2 inhibitor (NOX2-I) on
NOX2 complex assembly and sepsis-induced lung inﬂammation
were examined. Lung cytokine expression and neutrophil inﬂux
induced with sepsis in NOX21/1 mice was decreased by .50% in
NOX22/2 mice. LPS-induced TLR4 signaling evident by inhibitor of
NF-kB kinase-b and mitogen-activated protein kinase phosphorylation,

Postnatal inﬂammation and tissue injury
in the developing lung contribute to
the disrupted alveolar development
observed in premature infants with
bronchopulmonary dysplasia (BPD)
(1, 2). Risk factors associated with BPD,
such as hyperoxia, barotrauma, and
sepsis, trigger the production of reactive
oxygen species (ROS) in the premature

and nuclear factor-kB/AP-1 translocation were attenuated in
NOX22/2 mice. LPS increased matrix metalloproteinase 9
while decreasing elastin and keratinocyte growth factor levels
in NOX21/1 mice. An LPS-induced increase in matrix
metalloproteinase 9 and decrease in ﬁbroblast growth factor 7 and
elastin were not evident in NOX22/2 mice. An LPS-induced
reduction in radial alveolar counts and increased mean linear
intercepts were attenuated in NOX22/2 mice. LPS-induced NOX2
assembly evident by p67phox/gp91phox coimmunoprecipitation
was disrupted with NOX2-I. NOX2-I also mitigated LPS-induced
cytokine expression, TLR pathway signaling, and alveolar
simpliﬁcation. In a mouse model of neonatal sepsis, NOX2 regulates
proinﬂammatory TLR signaling and alveolar remodeling induced
by a single dose of LPS. Our results provide mechanistic insight into
the regulation of sepsis-induced alveolar remodeling in the
developing lung.
Keywords: nicotinamide adenine dinucleotide phosphate oxidase;

sepsis; Toll-like receptor signaling; neonatal lung injury;
bronchopulmonary dysplasia

lung, which contributes to lung
inﬂammation and matrix degradation
(3–5). Multiple investigators have shown
that markers of oxidant-mediated
lung injury, such as 8-Oxo-29deoxyguanosine, oxidized surfactant
phospholipids, F2-isoprostanes, and
nitrotyrosine, are elevated in the
bronchoalveolar lavage, serum, or urine

of premature infants who subsequently
develop BPD (4–7). Therapies to mitigate
oxidant stress, such as recombinant
superoxide dismutase and vitamin A,
have been used in premature infants to
decrease BPD, with limited success (8, 9).
The preterm infant lung is particularly
vulnerable to oxidant-mediated damage
because lung antioxidant enzymes are

( Received in original form January 5, 2016; accepted in final form June 28, 2016 )
This work was supported partly by grants 1R01HL128374-01 (V.S.) and 8KL2TR000056 (V.S.).
Author Contributions: Conception and design: H.L.M. and V.S.; data collection: H.L.M., S.X., S.M.M., and A.N.; analysis and interpretation: H.L.M., S.X., A.N.,
M.F.N., and V.S.; and drafting and editing the manuscript: all authors.
Correspondence and requests for reprints should be addressed to: Venkatesh Sampath, M.D., Children’s Mercy Hospital, 2401 Gillham Road, Kansas City, MO
64108. E-mail: vsampath@cmh.edu
This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org
Am J Respir Cell Mol Biol Vol 55, Iss 6, pp 767–778, Dec 2016
Copyright © 2016 by the American Thoracic Society
Originally Published in Press as DOI: 10.1165/rcmb.2016-0006OC on July 20, 2016
Internet address: www.atsjournals.org

Menden, Xia, Mabry, et al.: NOX2 Regulates Lung Inflammation and Simplification

767

ORIGINAL RESEARCH

Clinical Relevance
Our data provide mechanistic insight
into sepsis-induced alveolar
remodeling seen in premature infants
with bronchopulmonary dysplasia.
We demonstrate that nicotinamide
adenine dinucleotide phosphate
oxidase 2 regulates sepsis-induced
inﬂammatory signaling and alveolar
simpliﬁcation in the developing lung.
Use of a peptide inhbitor of
nicotinamide adenine dinucleotide
phosphate oxidase 2 during sepsis
attenuates neonatal lung injury,
suggesting a potential therapy for
neonatal lung protection during
sepsis.
developmentally regulated and not fully
functional until term gestation (3, 6). Gramnegative bacterial sepsis is a common
complication of preterm birth and is
associated with an acute increase in ROS,
lung inﬂammation, and the development of
BPD (10, 11). The redox-dependent
mechanisms regulating sepsis-induced
inﬂammation and alveolar remodeling in the
developing lung remain poorly understood
and are the focus of this study.
During sepsis, bacterial cell-wall
components such as LPS are recognized by the
Toll-like receptor (TLR) family of innate
immune receptors (12, 13). TLR-mediated
bacterial recognition triggers complex
signaling cascades, resulting in the activation
of transcription factors nuclear factor-kB
(NF-kB) and AP-1, which regulate
inﬂammation and tissue injury in the lung
(12). Activation of canonical TLR signaling
increases intracellular ROS, and TLRmediated inﬂammation has been shown
in vitro to be regulated by the nicotinamide
adenine dinucleotide phosphate oxidase
(NOX) enzymes (14–17). The NOX family of
oxidoreductases generates superoxide by one
electron reduction of molecular oxygen using
the reduced form of nicotinamide adenine
dinucleotide phosphate1 as substrate. The
seven NOX catalytic homologs differ in
subunit composition, tissue distribution,
and mode of activation (14, 16). Some
NOX isoforms, such as NOX4, are
constitutively active, whereas others are
activated by cellular stress, hormones,
cytokines, and bacterial ligands. NOX-derived
ROS play a key role in homeostatic cellular
768

signaling when compartmentalized and
regulated (16, 18). However, pathological
activation of NOX has been implicated in
various disease processes such as ischemiareperfusion, inﬂammation, hypertension, and
cancer (14, 18). In the lung, NOX isoforms
show cell-type–speciﬁc distribution and
function and are found in endothelial
cells, epithelial cells, ﬁbroblasts,
macrophages, and smooth muscle cells
(18). Prior work in our laboratory
demonstrated that nicotinamide adenine
dinucleotide phosphate oxidase 2 (NOX2)
regulates LPS (TLR4 agonist)–mediated
superoxide production and cytokine
expression in fetal lung endothelial cells
(15). To determine the in vivo relevance
of NOX2 in proinﬂammatory TLR
signaling, we used a mouse model to
investigate whether NOX2 regulated
sepsis-induced inﬂammation and alveolar
remodeling in the developing lung.
Lung development in rodents is similar to
that in premature infants because it progresses
through the saccular and alveolar phase after
birth (19). Traditionally, rodent models of
BPD have used hyperoxia, antenatal
endotoxin exposure, and mechanical
ventilation to induce acute lung
inﬂammation and alveolar remodeling in
the immature lung (20, 21). Although it is
accepted that systemic sepsis in the
premature infant is a major risk factor for
the development of BPD, the mechanisms
by which sepsis-induced acute lung
inﬂammation contributes to alveolar
simpliﬁcation in BPD remain poorly
understood (11, 22, 23). To investigate the
mechanisms underlying sepsis-induced
inﬂammation and alveolar remodeling
in the immature lung, we developed
a model of neonatal sepsis using
intraperitoneal LPS administration in
6-day-old mouse pups. We hypothesized
that LPS-induced acute lung inﬂammation
would remodel the developing lung and
that NOX2 deﬁciency would protect
against TLR-mediated lung injury. The
results of this study suggest that NOX2
regulates sepsis-mediated lung
inﬂammation and alveolar remodeling in
the developing lung.

Materials and Methods
Animal Model

Care of mice before and during
experimental procedures was performed

in accordance with the policies of the
Biomedical Resource Center, Medical
College of Wisconsin, Laboratory Animal
Research Core, University of Missouri–
Kansas City, and the National
Institutes of Health guidelines for the
care and use of laboratory animals. All
protocols had prior approval from the
Medical College of Wisconsin
Institutional Animal Care and Use
Committee (AUA 3464) and the
University of Missouri–Kansas City
Institutional Animal Care and Use
Committee (protocol number 1510). In
experiments using the NOX2 2/2 animal
model, timed breeding was used for
animal comparisons. When the pups
were at Day of Life 6, they received
intraperitoneal injection of 1 mg/kg LPS
(Sigma, St. Louis, MO), whereas the
control mice received an equal volume
injection of sterile saline solution. The
pups were killed at 3, 6, 24, 96, or
196 hours after LPS administration
using an intraperitoneal injection of a
ketamine and xylazine mixture (100
mg/kg, 10 mg/kg, respectively). For
experiments with the NOX2 inhibitor,
gp91phox ds-tat (10 mg/kg, NOX2inhibitor [NOX2-I]; Anaspec,
Fremont, CA), and the p38 inhibitor
SB202190 (10 mg/kg, p38-I; Abcam,
Cambridge, MA), drugs were injected
intraperitoneally 2 hours before
intraperitoneal LPS injection. Lungs were
harvested and used for experimentation
as described below.

Hematoxylin and Eosin Staining to
Assess Lung Development in Inﬂated
Mouse Lungs

NOX21/1 and NOX22/2 mouse pups were
killed 196 hours after intraperitoneal
injection of LPS or saline. The lungs were
inﬂated using a ﬁxed volume of formalin, as
described previously by Parkinson and
colleagues (24). Brieﬂy, using a catheter,
300 mL of formalin ﬁxative was used to
inﬂate the lungs after the mice were killed.
Precautions were taken to not over- or
underinﬂate the lungs. The lungs were
further ﬁxed in formalin before being
embedded in parafﬁn, cut into 4-mm
sections onto slides, and stained with
hematoxylin and eosin. The hematoxylin
and eosin slides were scanned using a
NanoZoomer slide scanner (Hamamatsu,
Bridgewater, NJ), and the scanned
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images were used at 403 for assessing
radial alveolar count (25) and mean
linear intercepts (26) following previously
used protocols. At least four mice

were used per condition in these
experiments. For radial alveolar counts,
quantiﬁcation was performed by
averaging 10 measurements per mouse.

For mean linear intercepts,
quantiﬁcations were performed by
averaging ﬁve high-power ﬁelds per
mouse.
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Figure 1. Lung cytokine expression and neutrophil influx after intraperitoneal (i.p.) LPS injection. Six-day-old nicotinamide adenine dinucleotide phosphate oxidase
2 (NOX2)1/1 and NOX22/2 pups were injected intraperitoneally with LPS or saline, and the lungs were harvested for real-time polymerase chain reaction and
protein analysis at 24 and 96 hours (A–C). The left lung was used for immunofluorescence studies (D–E). (A) TNF-a, keratinocyte-derived cytokine (KC), and IL-1b
mRNA expression quantified by real-time polymerase chain reaction after intraperitoneal LPS injections. *P , 0.01 (NOX21/1 control versus NOX21/1 i.p. LPS);
#
P , 0.02 (NOX21/1 i.p. LPS versus NOX22/2 i.p. LPS) (n = 5). (B and C) Homogenized lung lysates after intraperitoneal injections of LPS in mouse pups
were immunoblotted for intercellular adhesion molecule (ICAM-1) and IL-1b (B), with densitometric quantification of ICAM-1 and IL-1b shown graphically (C). *P ,
0.01 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.02 (NOX21/1 i.p. LPS versus NOX22/2 i.p. LPS) (n = 5). (D) Fluorescent microscope images depicting
neutrophil influx by LY6G immunofluorescence staining. LY6G is shown in green and DAPI in blue. Images are shown at 203 magnification. (E) Graphical
representation summarizing the data, with each mouse shown as an average of three representative images. *P , 0.05 (NOX21/1 control versus NOX21/1
i.p. LPS); #P = 0.01 (NOX21/1 i.p. LPS versus NOX22/2 i.p. LPS) (n > 4). ANOVA with post hoc tests was used for analysis of data. HPF, high-powered field.
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pretreated with intraperitoneal injection of
10 mg/kg of NOX2-I or p38-I or saline.
Mice were killed 24 hours after the NOX2-I
or p38-I injection, and harvested lung lobes
were used for RNA (complementary DNA,

Treatment of Mice with gp91 ds-tat
(NOX2-I) and SB202190 (p38-I)
Chemical Injections

Two hours before intraperitoneal injection
of LPS/saline, NOX21/1 mouse pups were

real-time polymerase chain reaction)
isolation and protein (Western blot)
quantiﬁcation, as described above. At least
four mice were used per experimental
condition.
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Figure 2. Lung matrix metalloproteinase 9 (MMP-9), tissue inhibitor of matrix metalloproteinase 1 (TIMP-1), elastin, and keratinocyte growth factor 7
expression after intraperitoneal LPS injection. Lungs were harvested from NOX21/1 and NOX22/2 mouse pups injected with intraperitoneal LPS or saline
after 24 or 96 hours for protein analysis. (A) Homogenized lung lysates were used to immunoblot MMP-9 and TIMP-1 at 24 hours; b-actin was used as a
loading control. (B) MMP-9 quantification by densitometry is shown graphically. *P , 0.01 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.01
(NOX21/1 i.p. LPS versus NOX22/2 i.p. LPS) (n > 4). (C and D) Elastin (C) and fibroblast growth factor 7 (FGF7) (D) mRNA expression was quantified by
real-time polymerase chain reaction 96 hours after intraperitoneal LPS injection. *P , 0.05 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.02
(NOX21/1 i.p. LPS versus NOX22/2 i.p. LPS) (n > 4). (E and F ) Clarified lung lysates obtained 96 hours after LPS treatment in pups were blotted for FGF7
and elastin (E ), with quantification by densitometry shown graphically (F ). *P , 0.01 (NOX21/1 control versus NOX21/1 i.p. LPS); #P = 0.01 (NOX21/1
i.p. LPS versus NOX22/2 i.p. LPS) (n > 4). ANOVA with post hoc tests was used for analysis of data.
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Results
NOX2 Regulates LPS-Mediated Acute
Inﬂammation in the Developing Lung

We examined the effect of NOX2 deﬁciency
on lung inﬂammation induced by
intraperitoneal LPS injection in 6-day-old
mice. Whole-lung TNF-a, keratinocytederived cytokine (KC), and IL-1b RNA
expressions were increased more than
fourfold at 24 and 96 hours after
intraperitoneal LPS (Figure 1A). LPSmediated increase in inﬂammatory gene
expression was attenuated by z50% in
NOX22/2 mice (Figure 1A). Similarly,
whole-lung protein expression of
intercellular adhesion molecule (ICAM-1),
which facilitates lung neutrophil inﬂux, and
IL-1b induced with systemic LPS were
attenuated in NOX22/2 mice (Figures 1B
and 1C). These data reveal that deﬁciency
of NOX2 attenuates the pulmonary
expression of proinﬂammatory cytokines
induced with systemic LPS in 6-day-old
mice. Neutrophil inﬂux is a prominent
feature of acute lung injury that contributes
to lung inﬂammation and matrix
degradation. To evaluate the effect of
NOX2 deﬁciency on LPS-mediated lung
neutrophil invasion, we performed
immunoﬂuorescence for Ly6G (a speciﬁc
marker for neutrophils) in 4-mM lung
sections 24 hours after intraperitoneal LPS.
LPS-induced lung neutrophil inﬂux at
24 hours was decreased by .60% in
NOX22/2 mice (Figures 1 D and 1E).
These data demonstrate that the lung
inﬂammation and neutrophil inﬂux
observed with systemic LPS is attenuated in
NOX22/2 mice.
Effect of NOX2 Deﬁciency on
Markers of Matrix Remodeling and
Lung Growth

To evaluate the effect of sepsis on matrix
degradation in the developing lung,
we assessed protein levels of matrix
metalloproteinase (MMP) 9 (MMP-9)
and the tissue inhibitor of matrix

metalloproteinase (TIMP) 1 (TIMP-1) after
intraperitoneal LPS in 6-day-old mice. LPS
administration induced lung MMP-9 levels
by more than threefold at 24 hours (Figures
2A and 2B). Lung TIMP-1 expression was
evident in control NOX21/1 mice and
remained unchanged after intraperitoneal
LPS (Figure 2A). In NOX22/2 mice, LPSinduced lung MMP-9 expression was
attenuated by .40% (Figures 2A and 2B)
when compared with NOX21/1 mice. Lung
TIMP-1 expression in control NOX22/2
mice showed a nonsigniﬁcant increase
when compared with NOX21/1 mice
but did not change with systemic LPS.
These data suggest decreased MMP-9–
dependent remodeling with sepsis in
NOX22/2 mice.
To examine the effect of systemic LPS
on pathways related to alveolar growth, we
quantiﬁed Keratinocyte growth factor
(ﬁbroblast growth factor 7 [FGF7]), a lung
growth factor, and elastin (27, 28). There

were no signiﬁcant changes in elastin and
FGF7 RNA or protein 24 hours after LPS in
NOX21/1 mice (data not shown), but both
RNA and protein expression of elastin and
FGF7 were reduced at 96 hours after LPS
(Figures 2C–2E). The LPS-induced decrease
in lung elastin RNA and protein expression
was attenuated in NOX22/2 mice (Figures
2C–2E). Interestingly, systemic LPS
appeared to induce FGF7 protein in
NOX22/2 mice, resulting in signiﬁcantly
higher lung FGF7 levels when compared
with NOX21/1 mice treated with LPS.
These data suggest that markers of lung
growth are decreased with LPS in
NOX21/1 mice but are preserved in
NOX22/2 mice.
NOX2 Regulates Pulmonary TLR
Pathway Activation in Sepsis

To investigate the mechanisms by
which NOX2 regulates sepsis-induced
inﬂammation in the developing lung, we
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Figure 3. Changes in inhibitor of NF-kB kinase-b (IKK-b), p38, c-Jun N-terminal kinase (JNK), and
inhibitor of NF-kB-a (IkB) phosphorylation after LPS injection: Six-day-old NOX21/1 and NOX22/2
mouse pups were exposed to intraperitoneal injections of LPS or saline, and the lungs were harvested
for Western blot. (A and B) Mouse lung lysates were used to assess IKK-b, p38, and JNK
phosphorylation 24 hours after intraperitoneal LPS treatment by immunoblotting (A), and blots were
quantified by densitometry (B). *P , 0.01 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.01
(NOX21/1 i.p. LPS versus NOX22/2 i.p. LPS) (n > 4). (C and D) Western blot (C) of mouse lung lysates
showing changes in IkB-a phosphorylation 24 hours after intraperitoneal injection of LPS, and
graphical representation (D) summarizing quantification by densitometry of IkB-a phosphorylation.
*P , 0.001 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.01 (NOX21/1 i.p. LPS versus
NOX22/2 i.p. LPS) (n > 4). ANOVA with post hoc tests was used for analysis of data.
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LPS-Mediated Lung NF-kB and
AP-1 Activation Is Attenuated in
NOX22/2 Mice

Activation of the transcription factors
NF-kB and AP-1in the lung during sepsis
regulates proinﬂammatory cytokine
expression (10). We therefore evaluated
lung NF-kB and AP-1 activation in
6-day-old mice by quantifying nuclear
translocation of the p65 and c-Jun subunits,
respectively, using immunoﬂuorescence.
772

AP-1 with sepsis is NOX2 dependent in the
developing lung. To conﬁrm NF-kB
activation after LPS, we performed a shift
assay for p65 in whole-lung nuclear
homogenates. After LPS treatment, there
was increased p65 in NOX21/1 lung
nuclear extracts, which was attenuated in
NOX22/2 mice (Figures 4D and 4E).

Twenty-four hours after systemic LPS,
there was increased nuclear staining of p65
(Figures 4A and 4C) and c-Jun (Figures 4B
and 4C) in lung sections. The number of
lung cells with nuclear staining of p65 and
c-Jun after LPS was attenuated in
NOX22/2 mice (Figures 4A–4C). These
data indicate that activation of NF-kB and
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examined the effect of NOX2 deﬁciency on
LPS-mediated canonical TLR4 pathway
signaling. Systemic LPS administration
robustly increased inhibitor of NF-kB kinase-b
(IKK-b) phosphorylation (Ser177/181) in the
lungs of 6-day-old mice, indicating TLR
pathway activation (Figures 3A and 3B).
LPS-mediated IKK-b phosphorylation was
inhibited by .50% in NOX22/2 mice
(Figures 3A and 3B). Activation of the
mitogen-activated protein kinase (MAPK)
p38 and c-Jun N-terminal kinase (JNK)
through phosphorylation is a key event that
contributes to TLR-mediated inﬂammation.
In NOX21/1 mice, intraperitoneal LPSinduced lung phosphorylation of p38
(Thr180/Tyr182) and JNK (Thr183/Tyr185)
was evident at 24 hours (Figures 3A and
3B). p38 and JNK phosphorylation induced
by systemic LPS were decreased in the
lungs of NOX22/2 mice. To examine the
role of p38 in enhancing NF-kB signaling
in our model, we performed additional
experiments with the speciﬁc p38 inhibitor
(p38-I, SB202190, 10 mg/kg) (29, 30).
Pretreatment with p38-I (2 hr) decreased
LPS-induced p38 (Thr180/Tyr182)
phosphorylation, NF-kB activation. and
proinﬂammatory cytokine expression in
NOX21/1 mice (see online supplement).
In canonical TLR signaling, IKK-b
phosphorylation mediates inhibitor of
NF-kB-a (IkB-a) phosphorylation and
ubiquitination, with subsequent release and
nuclear translocation of IkB-bound NF-kB.
To examine IkB-a cellular dynamics in
our model, we examined IkB-a
phosphorylation after systemic LPS. Lung
IkB-a (Ser32) phosphorylation was increased
with intraperitoneal LPS in NOX21/1 mice at
20 hours (Figures 3C and 3D). NOX2
deﬁciency attenuated the IkB-a (Ser32)
phosphorylation seen with systemic LPS
treatment (Figures 3C and 3D). These results
suggest that NOX2 regulates TLR pathway
kinase activation and IkB-a phosphorylation
during sepsis in the developing lung.
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Figure 4. Assessment of NF-kB (p65) and AP-1 (c-Jun) activation after intraperitoneal LPS injection.
Lung sections (4 mM) obtained from 6-day-old NOX21/1 and NOX22/2 mouse pups 24 hours after
treatment with LPS or saline were used for immunofluorescence studies. Lung nuclear extracts
obtained from pups 3 hours after treatment with LPS or saline were used for electrophoretic
mobility shift assay. (A) Confocal microscope images depicting nuclear activation of p65 by
immunofluorescence staining. p65 in the cytoplasm stains green and DAPI (nucleus) is blue; the light
blue staining is activated p65 in the nucleus. Images were captured at 633 magnification. (B)
Confocal microscope images depicting nuclear activation of c-Jun by immunofluorescence staining.
c-Jun in the cytoplasm stains red and DAPI is blue; the magenta staining is activated c-Jun in the
nucleus. Images are shown at 633 magnification. (C) Graphical representation summarizing data of
nuclear p65 and c-Jun, with each mouse shown as an average of three representative images. *P ,
0.01 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.01 (NOX21/1 i.p. LPS versus NOX22/2 i.p.
LPS) (n > 4). (D and E ) Lung nuclear extracts were used with an electrophoretic mobility shift assay
using NF-kB (p65) binding oligo. A gel-shifted band appears in LPS-treated NOX21/1 lungs (D and E ),
but not NOX22/2 lungs (E). There was no band present in the negative control (NC), which had a
combination of hot and cold probes. C, control.
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Effect of NOX2 Deﬁciency on
LPS-Mediated Pulmonary
Alveolar Remodeling

To evaluate the impact of systemic LPS on
lung development, we assessed mean radial
alveolar counts and mean linear intercepts
on Postnatal Day 15 after administering
intraperitoneal LPS on Postnatal Day 6.
Compared with control mice, LPS-treated
mice had a 50% decrease in mean radial
alveolar counts and a 40% increase in mean
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To investigate the therapeutic potential of
NOX2 activity modulation in sepsisinduced lung inﬂammation, we tested
intraperitoneal gp91phox ds-tat (NOX2-I,
10 mg/kg), a synthetic peptide that binds to
gp91phox and inhibits NOX2 assembly in
our model (31). First, we examined the
assembly of NOX2 complex in the lung by
immunoprecipitating gp91phox and
probing for the cytosolic subunit p67phox.
In control NOX21/1 mice, p67phox was
not bound to gp91phox. LPS treatment
induced the association of p67phox with
gp91phox in whole-lung homogenates,
suggesting activation of NOX2 complex
assembly (Figure 5A). LPS-induced lung
NOX2 assembly was inhibited in mice
pretreated (2 hr) with intraperitoneal
NOX2-I (Figures 5A and 5B). Consistent
with inhibition of lung NOX2 complex
formation with NOX2-I, LPS-induced lung
cytokine RNA expression and ICAM-1
expression at 24 hours were attenuated in
mice pretreated with intraperitoneal
NOX2-I (Figures 5C–5E). These data show
that NOX2 inhibition ameliorates LPSinduced inﬂammation in the developing
lung.
We next examined whether NOX2-I
inhibits proinﬂammatory TLR signaling in
6-day-old mice. LPS-induced IKK-b
(Ser177/181), p38 (Thr180/Tyr182), and JNK
(Thr183/Tyr185) phosphorylation in the lung
was attenuated in mice pretreated with
intraperitoneal NOX2-I (Figures 6A and
6B). Similarly, LPS-induced lung NF-kB
activation examined by quantifying p65
nuclear translocation 24 hours after LPS
was also decreased in mice pretreated with
NOX2-I (Figures 6C and 6D). These data
show that NOX2-I mitigates LPS-induced
inﬂammation in the developing lung by
modulating proinﬂammatory TLR
signaling.
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Figure 5. Effect of gp91phox ds-tat (NOX2 inhibitor [NOX2-I]) on lung NOX2 complex assembly and
inflammation after intraperitoneal LPS injection. Six-day-old NOX21/1 mouse pups were pretreated
with intraperitoneal NOX2-I (10 mg/kg) 2 hours before intraperitoneal injection of LPS or saline. (A and
B) Homogenized lung lysates obtained 6 hours after intraperitoneal LPS or saline injection were
immunoprecipitated for gp91phox, followed by Western blotting for p67phox and gp91phox (A),
analysis by densitometry shown (B). *P , 0.01 (control versus i.p. LPS); #P = 0.01 (i.p. LPS versus
NOX2-I 1 i.p. LPS) (n > 4). (C) Homogenized lung lysates were used to quantify TNF-a, KC, and
IL-1b mRNA expression by real-time polymerase chain reaction 24 hours after intraperitoneal injection
of NOX2-I. *P , 0.01 (control versus i.p. LPS); #P , 0.05 (i.p. LPS versus NOX2-I 1 i.p. LPS) (n > 4).
(D and E) Twenty-four hours after intraperitoneal injection of LPS or saline, mouse pup lungs were
homogenized, and the clarified lysates were immunoblotted for ICAM-1 (D); densitometric
quantification shown graphically (E). *P , 0.01 (control versus i.p. LPS); #P , 0.05 (i.p. LPS versus
NOX2-I 1 i.p. LPS) (n > 4). ANOVA with post hoc tests was used for analysis of data.

linear intercepts (Figure 7). These data are
supportive of disrupted lung development
with LPS treatment. Because NOX2
deﬁciency attenuates lung inﬂammation
after intraperitoneal LPS in our model,
we investigated whether less lung
inﬂammation in NOX22/2 mice translated
into improved lung development. In
NOX22/2 mice treated with LPS, mean
radial alveolar counts were signiﬁcantly
higher, whereas mean linear intercepts were
lower when compared with NOX21/1 mice
(Figure 7). To investigate the therapeutic
potential of inhibiting NOX2 in preventing
sepsis-induced alveolar remodeling, we
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tested NOX2-I. NOX21/1 mice
pretreated with NOX2-I had less alveolar
simpliﬁcation when compared with
NOX21/1 mice after LPS treatment
(Figure 7). These data suggest that NOX2
deﬁciency protects against LPS-mediated
alveolar remodeling in the developing lung.

Discussion
The key molecular players that regulate
sepsis-induced inﬂammation and alveolar
remodeling in the developing lung remain
poorly understood. The results of this study
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Figure 6. Effect of gp91phox ds-tat (NOX2-I) on lung Toll-like receptor pathway signaling and NF-kB
activation after intraperitoneal LPS injection. Six-day-old NOX21/1 mouse pups were pretreated with
intraperitoneal NOX2-I (10 mg/kg) 2 hours before intraperitoneal injection of LPS or saline. (A and B)
Homogenized lung lysates obtained 24 hours after intraperitoneal LPS injection were used to assess
the phosphorylation of IKK-b, p38, and JNK by immunoblotting (A), and blots were quantified by
densitometry (B). *P , 0.01 (control versus i.p. LPS); #P , 0.01 (i.p. LPS versus NOX2-I 1 i.p. LPS)
(n > 4). (C and D) Confocal microscope images depicting nuclear activation of NF-kB (p65) by
immunofluorescent staining (C). p65 is shown in green and DAPI (nucleus) is blue; the light blue
staining represents cells with p65 in the nucleus, suggesting NF-kB activation. (D) Graph
summarizing nuclear NF-kB (p65) data, with each mouse shown as an average of three
representative images. *P , 0.01 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.01 (NOX21/1
i.p. LPS versus NOX22/2 i.p. LPS). Images were captured at 633 magnification (n > 4). ANOVA with
post hoc tests was used for analysis.

establish that NOX2 regulates lung
inﬂammation in response to systemic LPS in
neonatal mice. Using both genetic and
peptide-inhibitor strategies, we show that
TLR signaling through the IKK-b/NF-kB
and MAPK/AP-1 pathways in sepsis is
regulated by NOX2. Sepsis-induced
cytokine expression, neutrophil inﬂux,
and alterations in markers of lung
growth/matrix remodeling were attenuated
with NOX2 deﬁciency. We also show that
sepsis-induced inﬂammation in late
774

saccular/early alveolar lung can disrupt
lung development, resulting in alveolar
simpliﬁcation akin to that observed in
premature infants who develop BPD in
relation to systemic sepsis. NOX2 inhibition
or deﬁciency attenuated sepsis-induced
alveolar remodeling in the immature lung.
Although our results provide novel insights
into the mechanisms underlying sepsisinduced alveolar remodeling in the
developing lung, lack of cell-type–speciﬁc
data is a limitation of the study.

An acute increase in lung cytokine
levels and neutrophil inﬂux have been
reported in infants or adults with sepsisinduced acute lung injury (10, 18, 32). In
our neonatal model of sepsis induced by
intraperitoneal LPS, we observed an acute
increase in lung expression of cytokines
TNF-a, KC (equivalent to human IL-8),
IL-1b, and ICAM-1, similar to studies of
sepsis-induced lung injury in adult rodent
models. To determine whether NOX2dependent signaling contributes to
inﬂammation in the developing lung, we
performed matched experiments in
NOX22/2 mice lacking the catalytic
subunit gp91phox. Sepsis-induced lung
cytokine expression was attenuated by
.50% in NOX22/2 mice. These data are
consistent with the ﬁndings of Imai and
colleagues (33), who showed that a
deﬁciency in pathogen-induced oxidative
stress protects against acute lung
inﬂammation. Imai and colleagues (33)
demonstrated that mice lacking p47phox
(cytosolic subunit of NOX2) or TLR4 are
protected against lung injury induced by
H5N1 pulmonary infection. Although our
model involved systemic LPS (a TLR4
ligand) injection, our data also suggest that
TLR-mediated lung inﬂammation is NOX2
dependent in neonatal mice. In contrast
with our data, the ﬁndings of Gao and
colleagues (32), who used a model of
Escherichia coli sepsis, showed that lung
bacterial clearance decreased in parallel
with increased lung polymorphonuclear
sequestration in mice lacking gp91phox or
p47phox. Their data suggest that lack of
NOX2 potentiates neutrophil inﬂux in
sepsis, in contrast with our data showing
decreased neutrophil inﬂux in NOX22/2
mice. However, Gao and colleagues (32) did
ﬁnd that sepsis-induced microvascular
permeability and injury were decreased in
NOX22/2 mice. Differences in our results
could potentially be explained by a celltype–speciﬁc function of NOX2 and the use
of live bacteria versus a selective TLR4
ligand in our study. In the study by Gao
and colleagues (32), lack of neutrophilic
NOX2 function inhibited bacterial
clearance, which triggered macrophage
inﬂammatory protein 2–induced neutrophil
inﬂux. However, decreased NOX2 function
in endothelial cells protected against
microvascular injury and ICAM-1–
mediated lung neutrophil inﬂux.
Interestingly, Gao and colleagues (32) did
ﬁnd, as in our study, that lung ICAM-1
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Figure 7. Changes in lung morphometry after LPS injection. NOX21/1, NOX22/2, and NOX21/1
pups pretreated with intraperitoneal NOX2-I were injected with LPS or saline intraperitoneally on Day
of Life 6, and lungs were inflation fixed for morphometric analysis. Mouse lung sections (4 mm) were
stained with hematoxylin and eosin, and pictures were scanned for analysis (A). Scale bars: 100 mm.
(B) Radial alveolar counts were performed by averaging 10 measurements per mouse. Graphical
representation summarizing radial alveolar counts is shown. *P , 0.01 (NOX21/1 control versus
NOX21/1 i.p. LPS); #P , 0.01 (NOX21/1 i.p. LPS versus NOX22/2 1 i.p. LPS); ##P , 0.01 (NOX21/1
i.p. LPS versus NOX21/1 1 i.p. LPS 1 NOX2-I) (n > 4). (C) Mean linear intercepts were performed by
averaging five areas per mouse. Graphical representation summarizing mean linear intercepts is
shown. *P , 0.01 (NOX21/1 control versus NOX21/1 i.p. LPS); #P , 0.01 (NOX21/1 i.p. LPS versus
NOX22/2 1 i.p. LPS); ##P , 0.01 (NOX21/1 i.p. LPS versus NOX21/1 1 i.p. LPS 1 NOX2-I).
Differences between NOX21/1 mice and NOX22/2 mice, as well as between NOX21/1 mice and
NOX21/1 treated with NOX2-I, were analyzed separately using ANOVA with post hoc tests.
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expression was attenuated in NOX22/2
mice with sepsis. In our model of systemic
LPS injection, lack of neutrophilic NOX2
function will not contribute to bacteriamediated neutrophil inﬂux. However,
NOX2 deﬁciency in the microvasculature
may attenuate ICAM-1 expression and
ICAM-1–mediated neutrophil inﬂux.
Others have shown that, consistent with
our data, systemic sepsis or systemic
viremia-induced lung injury in rodents is
attenuated by chemical quenching of ROS
or p47phox deﬁciency (33, 34). In
summary, NOX2 appears to play a
complex cell-type–speciﬁc role in sepsisinduced lung inﬂammation, with
neutrophilic NOX2 necessary for bacterial
clearance but with microvascular
NOX2 activation contributing to lung
inﬂammation. Experiments in mice with
cell-type–speciﬁc NOX2 deﬁciency are
necessary to dissect the dual role of NOX2
in sepsis.
During sepsis, bacterial ligands
such as LPS engage TLRs and activate
proinﬂammatory signaling, resulting in the
activation of transcription factors NF-kB
and AP-1 (12, 30, 32). Our results show
that intraperitoneal LPS robustly activates
IKK-b and MAPK (p38 and JNK)
phosphorylation in the developing lung,
and NOX2 deﬁciency inhibits canonical
TLR pathway signaling. Although oxidative
stress–mediated activation of protein kinase
C, phospholipase 2 activation, and tyrosine
phosphorylation have been reported before,
the mechanisms underlying redox
regulation of kinase activity in sepsis
remain unclear (32, 33, 35–37). To
investigate the mechanisms by which
NOX2 regulates LPS-induced lung
inﬂammation, we examined whether
activation of proinﬂammatory TLR
pathway kinases is NOX2 dependent in the
developing lung. Our data showing that
NOX2 regulates lung IKK-b and MAPK
(p38 and JNK) phosphorylation in sepsis
supports the possibility of a mechanism by
which cellular redox status, via NOX
enzymes, regulates innate immune
signaling via TLRs. These in vivo data are
consistent with studies from our group
showing attenuation of LPS-mediated IKK-b
phosphorylation with NOX2 silencing in
lung endothelial cells (15). Induction of
IKK-b and MAPK phosphorylation
with sepsis was associated with nuclear
localization of the p65 and c-Jun subunits
of NF-kB and AP-1, supporting pulmonary
775
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activation of transcription factors. NF-kB
and AP-1 activation in sepsis was also
evident in NOX22/2 mouse pups but it was
signiﬁcantly attenuated compared with
NOX21/1 mice. Although consistent with
the ﬁndings of studies reporting ROSdependent activation of NF-kB and AP-1
during sepsis-induced lung injury, our data
suggest that NOX2 regulates LPS-mediated
activation of redox-sensitive transcription
factors in the developing lung (38–42). ROS
generated from the mitochondrial transport
chain, uncoupled endothelial nitric oxide
synthase, and xanthine oxidase have been
reported to propagate lung inﬂammation
during sepsis (10, 43). NOX2-derived
superoxide can also interact with catalytic
products of the above enzymes to form
highly reactive ROS such as peroxynitrite,
which contribute to inﬂammation and
tissue damage (10, 14). Although our data
conﬁrm the role of NOX2 in lung
inﬂammation and alveolar remodeling,
future studies to dissect the cross-talk
between NOX2 and other redox pathways
in our model are planned. We used wholelung tissue for our experiments and
therefore are not able to discern the celltype–speciﬁc role of NOX2 in sepsisinduced lung inﬂammation. Because NOX2
is expressed in multiple lung cell types, we
sought to investigate the global effect of
NOX2 loss or suppression (gp91phox
ds-tat) on LPS-induced inﬂammation in
the developing lung (18). Future studies will
investigate the differential role of celltype–speciﬁc NOX2 function in sepsis.
These data provide new insights into the
mechanisms by which NOX2 regulates
proinﬂammatory TLR signaling during
sepsis in vivo.
Animal models to study the effects of
noxious stimuli on lung development in
BPD have focused on prenatal endotoxin
exposure, postnatal hyperoxia or hypoxia,
and mechanical ventilation (20, 21, 44). To
the best of our knowledge, this is one of the
ﬁrst studies to examine the mechanisms
underlying systemic sepsis-induced lung
remodeling, which is observed in premature
infants who develop “ new BPD” without
signiﬁcant exposure to hyperoxia or
ventilation (2). In our model, LPS-induced
inﬂammation in the developing lung results
in increased mean linear intercepts and
decreased radial alveolar counts, suggesting
that systemic sepsis alone causes alveolar
simpliﬁcation (1). Our data are in
agreement with studies showing that
776

intraamniotic endotoxin or neonatal
intratracheal LPS exposures remodel the
lung in rodents (45, 46), and suggest that
activation of proinﬂammatory TLR
signaling in the developing lung disrupts
lung morphogenesis. Consistent with this
postulate, NOX22/2 mice reveal decreased
TLR-mediated lung inﬂammation and less
alveolar simpliﬁcation when compared with
NOX21/1 mice after sepsis. Although lung
matrix remodeling is a complex process in
the developing lung, activation of MMPs in
the setting of decreased levels of TIMP is a
known cause of inﬂammation-dependent
lung matrix degradation (47). We observed
that lung MMP-9 levels increased with
systemic LPS, with no change in TIMP-1
expression. Lung MMP-9 induction in
sepsis was decreased in NOX22/2 mice,
suggesting decreased alveolar destruction.
Previous studies in premature infants
have shown that increased MMP-9 or
MMP-9/TIMP-1 levels are associated
with increased risk of BPD (48, 49).
Furthermore, in sepsis-related acute
respiratory distress syndrome, imbalances
in MMPs and their inhibitors, TIMPs, have
been reported in animal studies as well as in
humans (47, 50). To examine the
relationship between sepsis-mediated
alveolar simpliﬁcation and pathways related
to lung growth, we quantiﬁed FGF7
(keratinocyte growth factor) and elastin
expression in our model (27, 28, 51). We
found that LPS treatment decreased FGF7
and elastin expression in the lung, and that
NOX2 deﬁciency attenuated this response.
Differences in lung MMP-9 and FGF7
levels observed with sepsis might be
potential mechanisms contributing to
attenuated alveolar remodeling in
NOX22/2 mice. Further research is
required to understand the mechanisms
underlying increased MMP-9 in sepsis
and the function of NOX2 in regulating
MMP-9 and TIMP-1 in the developing
lung.
To test the potential therapeutic
beneﬁts of NOX2 inhibition on sepsisinduced lung inﬂammation, we performed
experiments with gp91phox ds-tat, a cellpermeable peptide that inhibits NOX2
activation by disrupting assembly of the
active NOX2 complex (31, 52). Data
showing coimmunoprecipitation of
p67phox with gp91phox 6 hours after
systemic LPS demonstrate that an active
NOX2 complex is assembled in the lung
during sepsis. Pretreatment with gp91phox

ds-tat decreased coimmunoprecipitation of
p67phox with gp91phox, conﬁrming
inhibition of lung NOX2 activation with the
peptide inhibitor. Although the mechanism
and speciﬁcity of gp91phox ds-tat has been
elucidated in vitro, these original data
validate its function in vivo (31, 53).
Consistent with the inhibition of lung
NOX2 assembly by gp91phox ds-tat, sepsisinduced cytokine and ICAM-1 expression
were attenuated in mice treated with the
peptide inhibitor. Furthermore, similar to
our data obtained in NOX22/2 mice,
gp91phox ds-tat decreased LPS-induced
lung TLR pathway activation, as evidenced
by decreased IKK-b/MAPK
phosphorylation and NF-kB activation.
Inhibition of proinﬂammatory TLR
signaling with NOX2-I preserved lung
architecture, as evidenced by increased
radial alveolar counts and decreased mean
linear intercepts. These data strongly
suggest that NOX2 inhibition during
neonatal sepsis attenuates lung
inﬂammation, tissue damage, and alveolar
remodeling. Although the use of gp91phox
ds-tat in an animal model of sepsis is
new, these data are consistent with other
reports that indicate NOX2-mediated
injury in hypertension, diabetes, and
inﬂammasome activation is inhibited with
gp91phox ds-tat (31, 54, 55). We used
gp91phox ds-tat before intraperitoneal
LPS injection to generate proof-of-principle
data as a potential therapeutic agent in
sepsis. Future studies must examine
whether gp91phox ds-tat decreases lung
inﬂammation if administered after LPS
injection, and whether it is effective
in the phase of sepsis caused by live
bacteria.
Conclusions

In summary, we developed a model of
systemic LPS injection in neonatal mice to
investigate the mechanisms by which
postnatal sepsis contributes to disrupted
alveolar development. We demonstrated
that systemic LPS administration activates
canonical TLR signaling in the developing
lung, which disrupts alveolar development,
resulting in a phenotype similar to the
alveolar simpliﬁcation observed in
premature infants with BPD. Using both
genetic and inhibitor studies, we showed
that NOX2 regulates proinﬂammatory TLR
pathway activation in sepsis and that NOX2
deﬁciency or inhibition attenuates sepsisinduced lung injury and alveolar remodeling
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in the developing lung. This study reveals
the mechanisms by which a key enzyme
family that regulates cellular redox signaling
modulates lung innate immune function in
sepsis. Investigating the effects of NOX2

manipulation on neonatal lung injury
induced by live bacteria, as well as dissecting
the cell-type–speciﬁc effects of NOX2
function in the pathophysiology of sepsisinduced lung inﬂammation and
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